RxDoctor Payments Data

Novreen Shahdad, MD

Neurology · Irving, TXNPI 1114159878

Payments from drug & device makers

$1,524in general payments, 2019–2025

Across 77 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$445
  • Lilly USA, LLC$151
  • GE HealthCare$119
  • Eisai Inc.$118
  • AstraZeneca$116
  • AbbVie$111
  • plus $464 from 14 others

What the payments were for

  • Food & beverage$1,524100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,524 in reported general payments places this provider in the 40th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$99,878
Medicare patients
358
Services billed
1,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate22$25,184
QuliptaAtogepant13$14,765
UbrelvyUbrogepant12$10,164
Memantine Hcl271$8,061
Carbamazepine ErCarbamazepine19$7,358
AptiomEslicarbazepine Acetate11$6,645
Levetiracetam165$6,130
Carbidopa-LevodopaCarbidopa/Levodopa162$4,527
Lacosamide17$4,298
Gabapentin139$3,197
RivastigmineRivastigmine Tartrate59$2,812
Donepezil Hcl251$2,656
Pregabalin59$2,308
Pyridostigmine Bromide17$1,758
Nortriptyline Hcl71$1,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$445$25,18422 claims
AbbVieQulipta, Ubrelvy$111$24,92925 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$34$1,75817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,246 neurology providers in Texas.

Other neurology in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →